Top 10 GLP-1 Compounds You've Never Heard Of (But Should Know)

The front runner of the next generation and the reason the whole field is buzzing. Retatrutide hits three receptors at once, adding glucagon to the GLP-1 and GIP combination that tirzepatide pioneered. The glucagon arm raises how much energy the body spends and goes after liver fat directly. In its pivotal TRIUMPH program, the highest dose produced average weight loss above 28 percent — the highest Phase 3 figure verified in the class so far. A regulatory filing is expected around the end of 2026.

The closest of this list to actual approval. CagriSema pairs semaglutide with cagrilintide, a long acting analog of amylin — a pancreatic hormone that curbs appetite and slows stomach emptying. The two work through different appetite pathways, so the effect adds up. In the REDEFINE 1 trial of more than 3,400 adults, patients who stayed on treatment lost close to 23 percent of body weight at 68 weeks. Novo Nordisk filed with the FDA in December 2025, with a decision expected in late 2026.

Survodutide flips two switches: GLP-1 for appetite and glucagon for energy burn and liver fat. Its real differentiator is organ level specificity. The glucagon component drives direct reduction of liver fat, which is why it earned FDA Breakthrough Therapy Designation for non-cirrhotic MASH, a serious fatty liver disease. Phase 3 obesity results from the SYNCHRONIZE program read out through 2026, and it may become a genuine option for people who need both weight loss and liver protection.

The one that could change access more than efficacy. Orforglipron is not a peptide at all — it is a small molecule, which means it can be made as a simple daily pill with no food or water timing restrictions like older oral semaglutide required. Weight loss in its ATTAIN program landed around 11 to 12 percent, lower than the injectables, but the convenience and cheaper manufacturing could put GLP-1 therapy in far more hands.

A single molecule that combines GLP-1 and amylin activity, developed in both oral and injectable forms. What drew attention was speed. An early oral trial showed roughly 13 percent weight loss in just 12 weeks — a pace that outran comparable drugs at the same point. Novo Nordisk advanced amycretin into Phase 3 on the strength of that early data. If the longer trials hold, it could sit among the highest efficacy obesity drugs ever tested.

Already approved in China and quietly advancing toward global markets, mazdutide is another GLP-1 and glucagon dual agonist. Its Phase 3 GLORY program in Chinese adults reported up to about 20 percent weight loss at the higher dose, along with improvements in cardiometabolic risk factors. It is a reminder that the pipeline is global, and that some of the most advanced data is coming from outside the usual Western trial centers.

Petrelintide is interesting precisely because it is not a GLP-1 drug. It is a long acting amylin analog tested as a standalone obesity medicine — one of the first to ask whether the amylin pathway alone can rival GLP-1 results with gentler tolerability. Its Phase 2 ZUPREME-1 trial reported about 10.7 percent weight loss at 42 weeks. Roche paid billions for the rights, a signal of how seriously the industry takes amylin as the next frontier.

VK2735 turned heads for how fast it worked. Its Phase 2 data showed close to 15 percent weight loss in only 13 weeks — an unusually rapid onset that generated real attention. The subcutaneous version has entered Phase 3 in the VANQUISH trial, and an oral formulation showed strong early numbers of its own. As a smaller company asset going head to head with pharma giants, it is one of the more closely watched names in the field.

Another GLP-1 and glucagon dual agonist, pemvidutide reported about 15.6 percent weight loss in its Phase 2b program along with high rates of MASH resolution. A notable practical feature is that it was studied without dose titration, meaning patients may not need the slow step-up schedule other drugs require. That could simplify the starting experience considerably, which matters more to real world patients than the trial data alone suggests.

MariTide does something deliberately different. Instead of chasing the highest weight loss number, it aims for a once monthly shot and for durability — with early signals suggesting weight can be maintained even after treatment stops. That last point matters enormously, because the hardest part of these drugs is what happens when you come off them. If the Phase 3 MARITIME data confirms lasting effect with far fewer injections, it could reshape how people think about staying on therapy long term.